Navigation Links
DNA with a twist: New company to search for cancer drugs and antibiotics
Date:2/13/2008

A new company has joined the fight against MRSA and cancer. Researchers at the John Innes Centre (Norwich) have launched a new company, Inspiralis Ltd, based around their expertise in DNA topoisomerases a group of enzymes that help DNA molecules to unravel and wind up properly and not to become tangled during replication.

DNA becomes tangled as a result of various cellular processes, such as replication, which ultimately stops these processes continuing. DNA topoisomerases untangle it. Without them cells die, says Inspiralis co-founder Dr Nicolas Burton.

Topoisomerases are already targets for several drugs, including anti-tumour drugs and antibiotics, such as ciprofloxacin the anti-anthrax drug. The search is now on for new ways of inhibiting them. Inspiralis Ltd make a range of products targeted to the pharmaceutical industry to enable drug-discovery work in this area including topoisomerase enzymes themselves as well as associated products.

A new high-throughput assay, developed recently in the laboratory of Prof. Tony Maxwell of the John Innes Centre (and co-founder of Inspiralis), will also provide a huge advance on the standard gel-based screening method for topoisomerase inhibitors. Inspiralis Ltd will develop the technique further as well as offering screening services to companies. The assay will potentially allow millions of compounds to be screened for activity rather than just hundreds, says Dr Burton.

The technology can now be accessed as a service or as a kit helping pharmaceutical companies and academics to screen for new and better cancer drugs and antibiotics.

Some powerful antibiotics and key anti-cancer drugs act by inhibiting topoisomerases. In cancer, cells rapidly divide in an uncontrolled manner and topoisomerase inhibitors can block this uncontrolled cell division.

Topoisomerase inhibitors are key targets for new drug development, says Mrs Alison Howells (co-founder). We can test potential new drugs against topoisomerases as well as help discover new inhibitors as a first step to developing brand new drugs.

Inspiralis is based at the Norwich Bio-Incubator at JIC and was founded with backing from the ICENI fund, a private investor and the John Innes Centre.

The high-throughput assay is patented by JICs and BBSRCs technology transfer company, Plant Biosciences Ltd, and non-exclusive licenses have already been granted to pharmaceutical companies.


'/>"/>

Contact: Zoe Dunford
zoe.dunford@bbsrc.ac.uk
44-016-032-55111
Norwich BioScience Institutes
Source:Eurekalert  

Related medicine news :

1. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
2. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
3. Cleveland-based Health Care Tech Company Within3 Names New CEO
4. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
5. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
8. Exponent to Present at the Upcoming Sidoti & Company Investor Forum and William Blair Small-Cap Growth Stock Conference
9. Perrigo Company to Host Analyst Meeting on September 18, 2007
10. The NeoStrata Company Appoints a New Vice President of Operations
11. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DNA with a twist: New company to search for cancer drugs and antibiotics
(Date:4/28/2016)... , ... April 28, 2016 , ... ... is proud to partner with AquaShieldUSA, the country's oldest waterproof cast protector ... and medical supply stores, the largest selection of daily, night, weatherproof and waterproof ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... successful events, attracting medical professionals from around the globe who attended a week’s ... Opening Ceremonies Sunday, April 17 included the introduction of the 2016 ARRS Distinguished ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the ... of childhood mortality. This is particularly true in underdeveloped parts of Africa where clean ... of New England’s campus in Tangier, Morocco, will examine this global health issue and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Year at VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® is ... and safety. The Healthy Ageing division can include everything from antioxidants, lipids, proteins, ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing ... Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in July ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... announced the launch of a Phase 2 clinical study ... hearing in patients undergoing cochlear implantation (CI) surgery. This ... patients in Germany and ... the middle ear at the time of surgery. "Despite ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
(Date:4/26/2016)... Bayer AG has reported first-quarter ... and amortization. The earnings are the result of a ... Xarelto and Eylea, drugs Bayer is banking on to ... date was extended by four years this week to ... to reach a value of USD 1,147.1 billion ...
Breaking Medicine Technology: